Research Highlights
Allison Sutton

$3.95
Journal of the Dermatology Nurses' Association
February 2011 
Volume 3  Number 1
Pages 50 - 52
 
  PDF Version Available!

ABSTRACT
Wagner, J., Ishida-Yamamoto, A., McGrath, J., Hordinsky, M., Keene, D., Woodley, D., et al. (2010). Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. New England Journal of Medicine, 363, 629-639.Recessive dystrophic epidermolysis bullosa (RDEB) is an inherited mechanobullous disease caused by mutations in the gene COL7A1, which encodes type VII collagen. Type VII collagen is a major component of anchoring fibrils, whose function is to tether the epidermal basement membrane to the dermis. This disease is often very severe and characterized by cycles of extensive blistering of mucocutaneous sites followed by ulcerations and scarring. Complications of scarring in the skin include flexion contractures of limbs and pseudosyndactyly or "mitten deformities" of the hands and feet. Complications of scarring in mucosal sites include narrowing of the oral cavity, limitation of tongue movement, loss of teeth, esophageal stricture formation, and narrowing of the airway. Because of these complications as well as the extensive wounds, caloric needs are increased, and the combination leads to malnutrition, anemia, and growth retardation. In the past, these patients died in infancy of sepsis and other complications of extensive blistering. Now, with improved nutritional and wound care, patients can survive into their teens or adulthood. Unfortunately, at that time, aggressive squamous cell carcinomas often occur within the abnormal skin, and many die of metastatic disease.To date, the care of RDEB patients has been palliative and restricted to treatment of individual wounds and systemic complications as they arise. This group hypothesized that allogeneic marrow contains stem cells capable of producing Type VII collagen, and therefore if transferred to patients deficient in this protein, it would ameliorate the manifestations of RDEB. They first studied this in mouse models and then conducted these Phase 1 and Phase 2 clinical trials. Between October 2007 and

Purchase Now !

To purchase this item, follow the instructions below. If you’re not already logged in, be sure to enter your login information below to ensure that your item is saved to your File Drawer after you purchase it.

Not a member? Join now for Free!


Cost:$3.95
1) If you're not already logged in, enter your information below to save this item in your File Drawer for future viewing.

User name:


Password


Forgot your user name or password?
2)  If you have a coupon or promotional code, enter it
here.(If not, just click Continue.


Digital Coupon: (optional)

3)  Click Continue to go to the next screen, where
you'll enter your payment details.






Featured Jobs



Benefits of Membership

FREE E-Newsletters
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues

CESaver
Join our CESaver program to earn up to 100 contact hours for only $34.95
Register Now

Lippincott's NursingCenter.com
Explore a world of online resources

Become a Member